Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial

Lancet (London, England) · 2026 Sep 30 · Klein KR, Wysham C, Tuttle KR et

By Maren Holt · Senior Reporter, GLP-1

Sep 29 20:00 ETSource: Lancet (London, England)

From the source

Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial
Lancet (London, England) · 2026 Sep 30 · Klein KR, Wysham C, Tuttle KR et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42815506/